Reactive oxygen species (ROS) and their products are components of cell signaling pathways and play important roles in cellular physiology and pathophysiology. Under physiological conditions, cells control ROS levels by the use of scavenging systems such as superoxide dismutases, peroxiredoxins, and glutathione that balance ROS generation and elimination. Under oxidative stress conditions, excessive ROS can damage cellular proteins, lipids, and DNA, leading to cell damage that may contribute to carcinogenesis. Several studies have shown that cancer cells display an adaptive response to oxidative stress by increasing expression of antioxidant enzymes and molecules. As a double-edged sword, ROS influence signaling pathways determining beneficial or detrimental outcomes in cancer therapy. In this review, we address the role of redox homeostasis in cancer growth and therapy and examine the current literature regarding the redox regulatory systems that become upregulated in cancer and their role in promoting tumor progression and resistance to chemotherapy.
1. Pathophysiology of Reactive Oxygen Species and Antioxidant Defenses
Reactive oxygen species (ROS) are highly reactive molecules that are principally derived from the oxygen that is consumed in various metabolic reactions occurring mainly in the mitochondria, peroxisomes, and the endoplasmic reticulum. ROS include the superoxide anion (O2∙-) and hydroxyl radicals (OH∙) as well as nonradical molecules such as hydrogen peroxide (H2O2) [1]. H2O2 is the more stable and diffusible form of ROS, it is selectively reactive towards cysteine residues on proteins, and, in the low nanomolar range, it can control cellular signaling (Figure 1).
Redox homeostasis is a balance of ROS generation and elimination. Mitochondria, NAPH oxidase (NOX), and endoplasmic reticulum are the three major intracellular sources of ROS. Anion superoxide (O2∙-) is the principal form of ROS and can be rapidly converted into hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 can be catalyzed to hydroxyl radical (OH∙) in the presence of Fe2+ or Cu2+ ions or be converted to H2O by catalase. The amount of H2O2 is decisive for the cell fate: low and intermediate levels of the peroxide stimulate loss of cell homeostasis and increased adaptation to stress leading to neoplastic transformation while high levels induce cell death.
ROS are mainly produced by the mitochondrial respiratory chain and also by enzyme-catalyzed reactions involving NADPH oxidase (NOX), xanthine oxidase, nitric oxide synthase (NOS), arachidonic acid, and metabolizing enzymes such as the cytochrome P450 enzymes, lipoxygenase, and cyclooxygenase [2] (Figure 1).
The modulation of intracellular ROS levels is crucial for cellular homeostasis, and different ROS levels can induce different biological responses. At low and moderate levels ROS can act as signaling molecules that sustain cellular proliferation and differentiation and activate stress-responsive survival pathways [3]. For instance, ROS can stimulate the phosphorylation of protein kinase C (PKC), p38 mitogen-activated protein kinase (p38 MAPK), extracellular signal-regulated kinase (ERK)1/2, phosphoinositide 3-kinase/serine-threonine kinase (PI3K/Akt), protein kinase B (PKB), and JUN N-terminal kinase (JNK) [4–6]. ROS are also involved in the increased expression of antioxidant genes related to the activation of transcription factors such as the nuclear factor erythroid 2-related factor 2 (Nrf2), activator protein 1 (AP-1), nuclear factor κB (NF-κB), hypoxia-inducible transcription factor 1a (HIF-1a), and p53 [7–9].
At high levels, ROS promote severe cell damage and death. Cancer cells display elevated ROS compared to normal counterparts as the result of the accumulation of intrinsic and/or environmental factors. The more relevant factors include hypoxia, enhanced cellular metabolic activity, mitochondrial dysfunction, oncogene activity, increased activity of oxidases, lipoxygenases and cyclooxygenases, and the cross talk between cancer cells and immune cells recruited to the tumor site. Recent research has revealed that conditions inducing oxidative stress lead the neoplastic cells to develop powerful antioxidant mechanisms.
Several types of antioxidants play important roles in ROS homeostasis, including dietary natural antioxidants (e.g., vitamins A, C, and E), endogenous antioxidant enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, and peroxiredoxins), and antioxidant molecules (e.g., glutathione, coenzyme Q, ferritin, and bilirubin).
Superoxide Dismutases. Superoxide dismutases (SOD) were the first characterized antioxidant enzymes [10] able to dismutate two O2∙- anions into H2O2 and molecular oxygen. Three different types of SOD are expressed in human cells: copper-zinc SOD (CuZnSOD), which is present mainly in the cytoplasm, manganese SOD (MnSOD), located in the mitochondria, and extracellular SOD. It has been demonstrated that mice lacking MnSOD produce a massive oxidative stress and die perinatally [11] while CuZnSOD-deficient mice have persistent oxidative damage and develop hepatocellular carcinoma [12]. In addition, a variant allele of MnSOD has been associated with an elevated risk of prostate [13], lung [14], ovarian cancers [15], and non-Hodgkin’s lymphoma [16].
Catalase. Catalase, a heme enzyme that catalyzes the reaction that converts two molecules of H2O2 to O2 and two molecules of H2O, is responsible for the detoxification of various phenols, alcohols, and hydrogen peroxide. Several epidemiologic studies have investigated the relationship between the mutations of catalase and human cancer but the results obtained are contradictory. In fact, a decreased catalase activity has been found both in blood samples and in tissues of breast cancer patients [17, 18] and in oral and pancreatic carcinomas [19, 20]. However, an increase in catalase levels has been reported in breast cancer tissue [21], malignant mesothelioma, and colorectal carcinoma [22, 23].
Peroxiredoxins. Peroxiredoxins (PRDXs) are a family of six isoenzymes able to reduce alkyl hydroperoxides and H2O2 to their corresponding alcohol or H2O. PRDXs are considered to be amongst the most important antioxidant enzymes, known to balance the production of cellular H2O2 which is essential for cell signaling and metabolism [24]. Under oxidative stress conditions, PRDXs are upregulated by Nrf2 activity and several studies have shown that the overexpression of PRDXs could either inhibit the development of cancer or promote growth of cancers [25].
In fact, PRDX1 interacts with the c-Myc oncogene and suppresses its transcriptional activity playing a tumor-suppressive role in breast cancer development [26, 27]. On the contrary, PRDX1 is associated with the promotion of oral, esophageal, lung, hepatocellular, and pancreatic carcinoma by upregulating heme oxygenase 1 and activating the NF-κB pathway [28–31]. Moreover, also PRDX2 promotes colorectal carcinoma through upregulation of Wnt/β catenin and prostate cancer through upregulation of androgen receptor activity [32, 33]. Furthermore, several studies have demonstrated that the overexpression of PRDX1, PRDX2, and PRDX3 has an important role in many cases of drug resistance and that the therapeutic agents targeting these PRDXs are frequently studied for the treatment of cancer [34]. While PRDX3, PRDX4, and PRDX6 play a tumor-promoting role in the progression of many cancers [35–37], PRDX5, similar to PRDX1, has an antitumor effect in breast cancer development [38, 39].
Thioredoxins. Thioredoxins (Trxs) protect cells from oxidative stress by means of their 2-cysteine active site that reacts with ROS and is able to reduce oxidized proteins. They also serve as hydrogen donors to the thioredoxin-dependent peroxide reductases. Trx1, expressed in the cytoplasm and the nucleus, and Trx2, expressed in the mitochondria, are indispensable for cell survival [40]. Nuclear Trx1 has been shown to be overexpressed in in situ breasttumors [41], in melanoma, lung, colon, cervix, gastric, liver, and pancreatic carcinomas [42–45].
Glutathione. Glutathione (GSH) is the major cellular thiol protein, consisting of three amino acids glutamine, cysteine, and glycine, and it participates in antioxidant defense, in the detoxification of xenobiotics, and in many metabolic processes such as the synthesis of proteins and nucleic acids [46]. It is synthesized from L-glutamate, L-cysteine, and glycine in two consecutive steps, catalyzed by glutamate-cysteine ligase (GCL) and glutathione synthase (GS) [47]. GCL is considered the rate-limiting enzyme of GSH synthesis. While GSH loss, or a decrease in glutathione/glutathione disulphide ratio (GSH/GSSG), leads to an increased susceptibility to oxidative stress and to carcinogenesis, elevated GSH levels increase the antioxidant capacity of many cancer cells enhancing their resistance to oxidative stress [48]. Remarkably, the inhibition of GSH and Trx dependent pathways induces a synergistic cancer cell death, demonstrating the importance of these two antioxidants in favoring tumor progression [49]. Glutathione peroxidases (GPx) are another group of enzymes capable of reducing hydroperoxides, including lipid hydroperoxides, using GSH as a substrate and generating GSSG which is, once again, reduced by the specific enzyme glutathione reductase (GR). A proline-leucine substitution at codon 198 of human GPx has been associated with the increased risk of breast [50, 51], lung [52], and bladder cancer [53].
Heme Oxygenase. Heme oxygenase (HO)-1 is the first rate-limiting enzyme in the degradation of heme into biliverdin/bilirubin, carbon monoxide (CO), and free iron [54]. Normally expressed at low levels in most of the mammalian tissues, HO-1 expression is efficiently upregulated by the availability of its substrate heme and by different stress stimuli such as heavy metals, UV irradiation, ROS, nitric oxide, and inflammatory cytokines [55]. By increasing the availability of bilirubin, ferritin, and CO, with antioxidant and antiapoptotic properties, HO-1 is recognized as a key player in the maintenance of cellular homeostasis and in the adaptive response to cellular stressors [56]. For this reason, HO-1 activity is crucial in the protection of healthy cells, maintaining cell viability and counteracting ROS-mediated carcinogenesis as well [57]. However, the involvement of HO-1 in cancer cell biology has been proven [58] and the upregulation of HO-1 has been widely related to cancer cell metastatic and proangiogenetic potential and poor prognosis [59–61]. Nevertheless, the role of HO-1 seems to be strongly dependent on the types of tumor considered. For instance, in breast cancer cells, HO-1 activity reduces cell proliferation and favors the efficacy of certain drugs [62, 63]. Thus, it is important to note that the metabolic status of cancer cells may influence HO-1 expression that is dependent on different signaling pathways and transcription factors, suggesting a possible, but not completely understood, regulation of HO-1 [64]. In addition, it has been recently demonstrated that the response of myeloma cells to bortezomib could be due to the noncanonical functions of HO-1 which translocates to the nucleus where it plays a role in genetic instability, favoring cancer progression independently of its enzymatic activity [65]. Within this context, the nuclear localization of HO-1 has also been demonstrated to be involved in the gain of resistance to other chemotherapeutic agents such as imatinib in chronic myeloid leukemia [66]. As a whole, these findings open up a new scenario of the role of HO-1 in cancer cell biology.
2. Redox-Signaling Pathways Involved in Tumorigenesis and in Tumor Progression
In many tumors dysregulation of proliferation, apoptosis, and autophagy depends on the constitutive activation of redox-sensitive targets such as protein kinase C (PKC), protein kinase B (Akt), mitogen-activated protein kinases (MAPK), and ataxia telangiectasia mutated (ATM) kinase [135].
2.1. Protein Kinase C
Among redox-modulated signaling molecules playing a role in cancer, PKC may be activated by oxidative modifications of its enzymatic structure [136–138]. In this regard, in vivo and in vitro studies have demonstrated that high doses of prooxidant compounds cause PKC inactivation and proteolytic degradation while low doses induce the stimulation of the kinase activity [139–142].
For most PKC isoenzymes there is conflicting evidence as to whether they act as oncogenes or as tumor suppressors [143]. For example, the overexpression of PKCα has been demonstrated in prostate, endometrial, and high-grade urinary bladder carcinoma [144] while downregulation of PKCα has been described in basal cell carcinoma and colon cancers [145, 146]. Also PKCβ overexpression is an early event in colon cancer development [147] and the transgenic overexpression of PKCβII induces hyperproliferation and invasiveness of intestine epithelial cells [148]. It has been reported that PKCβ isoenzyme is responsible for the activation/phosphorylation of p66/shc, which can bind to cytochrome c and stimulate the generation of ROS [149]. Recent findings have demonstrated that PKCα plays a critical role in hepatocarcinoma development by inducing DUOX (a member family of NOX) expression and ROS production [150]. Moreover, also PKCδ has been shown to be implicated in NOX activation that via alterations of redox state influence retinoic acid-induced differentiation of neuroblastoma cells [151]. Likewise, PKCδ can act as either a positive or a negative regulator of tumor progression [152, 153]. Specifically, PKCδ may be overexpressed in colon cancers and downregulated in malignant gliomas, bladder carcinomas, and endometrial tumors [154]. Moreover, while the upregulation of PKCδ, in breast cancer patients, has been linked with the acquisition of resistance to tamoxifen [155] the overexpression of PKCδ in neuroblastoma cells induces apoptosis by sensitizing cells to etoposide [156].
2.2. PI3K/AKT
PI3K/AKT signaling contributes to tumorigenesis and to the expression of different cancer hallmarks. It facilitates the invasion and metastasis of cancer cells by promoting matrix metalloproteinase-9 (MMP-9) secretion [157] and by inducing the epithelial mesenchymal transition (EMT) [158] while it also increases telomerase activity and replication by activating telomerase reverse transcriptase (TERT) [159].
Furthermore, the PI3K/AKT signaling pathway has been found to activate NOX with production of ROS that on one hand may increase the genomic instability of cancer cells [160] and on the other hand may render cancer cells more sensitive to chemotherapy [161]. In addition, the upregulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor gene frequently deleted or mutated in many human cancers, has been demonstrated to reduce ROS generation by regulating the PI3K/AKT pathway [162]. ROS-dependent PTEN inactivation shifts the kinase-phosphatase balance in favor of tumorigenic tyrosine kinase receptor signaling through Akt, which inhibits apoptosis by phosphorylating and inactivating several targets, including Bad, forkhead transcription factors, and c-Raf and caspase-9 [163].
2.3. Apoptosis Signal-Regulating Kinase 1 (ASK1) and p38 MAPK
Apoptosis signal-regulating kinase 1 (ASK1) has been shown to act as a redox sensor by mediating the sustained activation of JNK and p38MAPK [164] resulting in apoptosis upon oxidative stress conditions [165]. In its inactive state, ASK1 is coupled to the reduced form of Trx 1 that induces its ubiquitination and degradation [166].
As above reported, p38 MAPK is able to inhibit tumor initiation by inducing apoptosis, by regulating cell cycle progression, and/or by inducing premature senescence of primary cells [167] This protein kinase contains four active cysteine residues that can be potentially oxidized. Although the activation of p38α is normally associated with antiproliferative functions [168, 169], several studies indicate that p38α can positively modulate cancer progression [170] as observed in malignant hematopoietic cells [171] and in other tumor cell lines [172]. Consistent with the prooncogenic role of p38MAPK, the inhibition of p38MAPK activity has been found to impair the proliferation and anchorage-independent growth of neuroblastoma cells [173].
2.4. Ataxia Telangiectasia Mutated (ATM) Kinase
A critical enzyme in maintaining genome stability is ATM, which can regulate DNA damage repair [174]. In fact, ATM upregulates the glucose-6-phosphate dehydrogenase to promote NADPH production and thus reduces ROS levels [175]. In cancer stem cells (CSCs), the ATM signaling pathway is highly active. In CD44+/CD24− stem-like cells, compared with other cell populations from breast cancer, the expression of ATM was significantly increased [176] and the employment of an ATM inhibitor reversed their resistance to radiotherapy, suggesting the importance of ATM signaling in CSC formation [176].
3. Role of Transcription Factors as ROS Modulators in Carcinogenesis and Cancer Progression
Many transcription factors are key players in regulating several pathways involved in carcinogenesis and cancer progression. Through their binding to the gene promoter regions, they can transactivate or repress the expression of antioxidant genes leading to the alteration in redox state and changes in proliferation, growth suppression, differentiation, and senescence.
3.1. p53
p53 functions as a transcription factor able to activate or repress a large number of target genes that are involved in cell cycle control, DNA repair, apoptosis, and cellular stress responses [177]. It is kept at low levels by several E3 ubiquitin ligases, such as Mdm2, responsible for its degradation [178], and it is stabilized by posttranslational modifications such as phosphorylation, acetylation, and methylation [179, 180].
p53 has a controversial role in ROS regulation as it can promote both pro- and antioxidant responses [174].
Stress-induced p53 activation leads to the upregulation of several genes encoding ROS-generating enzymes, such as NQO1 (quinone oxidoreductase) [181] and proline oxidase (POX) [182], and redox-active proteins, including Bax and Puma. In particular, p53-induced ROS overproduction may be due to the overexpression of Puma, a critical mediator of mitochondrial membrane impairment [183], to the transcriptional activation of p67phox, a component of NADPH oxidase responsible for O2∙- production [184] and to the action of p66Shc which oxidizes cytochrome c and affects mitochondrial permeability [149].
Moreover, the prooxidant activity of p53 has been found to be modulated by several genes named PIG1–13 (p53-inducible genes 1–13) which are able to encode redox-active proteins [181]. In particular, PIG1, a member of the galectin family, is involved in superoxide production; PIG3, homolog of NADPH-quinone oxidoreductase, is a potent ROS generator and PIG8, a human homolog of mouse E-24 gene, is a quinone able to regulate ROS [181].
In contrast, p53 is also able to transactivate different genes controlling antioxidant response in order to maintain ROS production at nontoxic levels [185]. In fact, p53 has been found to activate MnSOD expression via the direct recognition of the MnSOD human gene promoter [186] and to induce the expression of heme-oxygenase-1 (HO-1) by directly binding to the HO-1 promoter, favoring cell survival [187].
Another important antioxidant target of p53 is Tp53-induced glycolysis and apoptosis regulator (TIGAR) [188]. TIGAR encodes a protein that is similar to the glycolytic enzyme fructose-2,6-bisphosphatase, which degrades fructose-2,6-bisphosphate [189]. A decrease in fructose-2,6-bisphosphate levels inhibits the activity of the rate-limiting enzyme phosphofructokinase I (PFK1), thereby blocking glycolysis and promoting the shuttling of metabolites to the pentose phosphate pathway (PPP). By upregulating TIGAR, p53 amplifies PPP-mediated NADPH production that is required by glutathione reductase in order to convert GSSG to GSH. A third important antioxidant target of p53 is glutaminase 2 (GLS2) that converts glutamine to glutamate which is subsequently converted to GSH via GCLC and GCLM [190].
3.2. Nrf2
Nrf2 is a transcription factor that controls not only the expression of antioxidants as well as phase I and phase II drug metabolizing systems, but also multidrug-resistance-associated protein transporters [58]. In a resting state, Nrf2 is sequestered in the cytoplasm through the binding with Keap1, responsible for Nrf2 ubiquitination and proteasomal degradation via Cul3. Oxidative/electrophilic stress causes a conformational change in Keap1-Cul3 by acting on specific residues in Keap1, leading to Nrf2 dissociation. Thus, Nrf2 translocates to the nucleus where it dimerizes with a small Maf protein and binds to the antioxidant response element (ARE) sequence within regulatory regions of a wide variety of target genes [191, 192]. In fact, Nrf2 is essential for the expression of stress-responsive or cytoprotective enzymes such as NQO1, SODs, HO-1, catalase, and Trx. In addition, Nrf2 activation regulates GSH levels and metabolism by inducing the expression of GCL, GS, GSH S-transferases (GSTs), GR, and GPx [193, 194].
Several mechanisms have been shown to be involved in the constitutive activation of Nrf2 in cancer cells, mainly gain-of-function mutations in Nrf2 and loss-of-function mutations in Keap1 [195–198]. Shibata et al. [199] have reported that Keap1 and Nrf2 mutations, in lung cancer, are responsible for the upregulation of ARE-modulated genes, which favor cancer promotion and/or progression [58]. Recently, these alterations of Keap1/Nrf2 pathway have been considered among the potential novel targets for the treatment of lung adenocarcinoma [200].
Among Nrf2 target genes glucose-6-phosphate dehydrogenase, phosphogluconate dehydrogenase, transketolase, and transaldolase I are responsible for NADPH and purine regeneration and then accelerate cancer cell proliferation [201]. Moreover, Nrf2 is directly involved in the basal expression of the p53 inhibitor Mdm2, through the binding to the ARE sequence located in the first intron of this gene, and inhibits cell death [202]. Cancer cells with high levels of Nrf2 have been shown to be less sensitive to etoposide, cisplatin, and doxorubicin [203] and our studies demonstrated that activation of Nrf2 and of its target genes plays a key role in the resistance of neuroblastoma cells to GSH depletion or proteasome inhibition [85, 204].
3.3. NF-κB
The transcriptionfactor NF-κB plays a critical role in cell survival, proliferation, immunity, and inflammation [205]. In stimulated cells, I-κB, an endogenous inhibitor able to retain NF-κB in the cytoplasm, is phosphorylated by I-κB kinase (IKK) which leads to I-κB ubiquitination and proteasomal degradation and induces NF-κB translocation to the nucleus where it can modulate the transcription of its target genes [206]. Morgan and Liu showed that ROS may regulate NF-κB activation to express antioxidant genes coding MnSOD, Cu,Zn-SOD, catalase, Trx, GST-pi, HO-1, and GPx [207]. NF-κB is also involved in the regulation of some enzymes catalyzing ROS production such as NOX2, xanthine oxidoreductase, NOS, and COX-2 [208].
NF-κB activation leads to the development and/or progression of cancer by upregulating several genes involved in cell transformation, proliferation, and angiogenesis [209]. In this regard, it has been found that NF-κB activation and ROS production promote the progression of hepatocellular carcinoma [210] and the initiation of colorectal cancer [211]. Moreover, as observed in high-risk myelodysplastic syndrome and in AML patients, NF-κB activation, due to the constitutive activation of ATM [212], is critical for the survival of human leukemia cells [213] by increasing MnSOD activity, reducing ROS levels and inhibiting oxidative cell death.
3.4. HIF-1
Hypoxia-inducible factor (HIF-1) is a heterodimeric transcription factor composed of an α-subunit (HIF-1α) and a β-subunit (HIF-1β) [214]. The expression of HIF-1α is mainly regulated at the posttranslational level in an oxygen-dependent manner and is largely responsible for the regulation of HIF-1 activity [215].
It has been demonstrated that HIF-1α interacts with the HIF-1β and acts as a transcription factor able to induce the expression of genes involved in metabolic adaptation, such as hexokinase II (HK II) and pyruvate dehydrogenase kinase 1 (PDK1) [216], and the expression of genes involved in improving oxygen availability [217, 218] and shifting the glucose metabolism from mitochondrial oxidative phosphorylation to anaerobic glycolysis [219].
In addition, it has been demonstrated that ROS, via the modulation of PI3K/AKT and ERK pathways, are able to activate HIF-1 in hypoxic tumors [220]. In fact, HIF-1 overexpression correlates with poor outcomes in patients with head, neck, nasopharyngeal, colorectal, pancreatic, breast, cervical, bone, endometrial, ovarian, bladder, glial, and gastric cancers [9] and it is associated with refractiveness to conventional therapies [221].
4. ROS-Modulating Agents Undergoing Clinical Trials in Oncology
Several anticancer drugs are able to produce high levels of ROS leading to DNA damage and apoptosis [222, 223] that can be further stimulated by depleting cancer cell of GSH. The following compounds alter the intracellular redox state and induce cell death; for this reason some of them have been employed to improve the cytotoxic effects of conventional drugs (Table 1).
ROS modulating drugs undergoing clinical trials in oncology.
Drug
Mechanism of action
Cancer type
Outcome
Ref.
L-Buthionine-sulfoximine
Inhibits GSH synthesis; activates PKCδ
NeuroblastomaMelanoma
Efficacious in vitro
[67–73]
Menadione
Depletes GSH; activates ERK1/2 and p38MAPK
Gastrointestinal and lung cancer
Under clinical trial
[74–77]
Imexon
Depletes intracellular thiols; increases AP-1 and Nrf2-DNA binding activity
Advanced breast cancer; NSCLC; prostate and pancreatic tumors
Efficacious
[78–82]
Disulfiram
Oxidizes GSH and inhibits proteasome; activates JNK; inhibits Nrf2 and NF-κB
Metastatic melanoma; liver cancer
Under clinical trial
[68, 83, 84]
Bortezomib
Inhibits proteasome activity; activates NF-κB; activates Nrf2 and upregulates HO-1
Myeloma, leukemia, AML, myelodysplastic syndrome, neuroblastoma, prostate cancer
Under clinical trial
[85–90]
NOV-002
Oxidizes GSH and induces S-glutathionylation
NSCLC; breast and ovarian cancer
Efficacious
[91–93]
Ezatiostat
Inhibits GST-P1 and activates JNK/ERK
Myelodysplastic syndrome
Under clinical trial
[94]
PX-12
Inactivates Trx-1
Advanced solid tumors
Efficacious
[95–97]
Dimesna
Targets Trx and Grx
Ovarian carcinoma, NSCLC
Efficacious
[95, 98, 99]
Motexafin gadolinium
Inhibits Trx
Pancreatic, biliary and haematological cancer, renal carcinoma
Under clinical trial
[97, 100–102]
Arsenic trioxide
Oxidizes GSH and thiol enzymes
APL, melanoma
Efficacious
[68]
L-Buthionine-S,R-sulfoximine (BSO) induces oxidative stress by inhibiting GSH biosynthesis [67] and it synergizes with cytotoxic chemotherapeutic agents, including arsenic trioxide, cisplatin, doxorubicin, and melphalan [68]. Our studies have demonstrated that BSO-induced ROS overproduction and apoptosis of neuroblastoma cells is mediated by PKCδ activation [69–72] which is crucial for the sensitization of cancer cells to BSO and to etoposide [156]. In this context, BSO plus melphalan is currently undergoing clinical evaluation in children with neuroblastoma and in patients with persistent or recurrent stage III malignant melanoma [73].
Menadione (also known as vitamin K3) is a synthetic derivative of vitamins K1 and K2. The oxidative stress generated by menadione is dose-dependent and is due to GSH depletion capable of inducing cell death [74]. Moreover, a recent study reported that menadione analogues at submicromolar concentrations activate apoptosis of myeloid leukemia cells via the activation of ERK 1/2 and p38MAPK [75]. In vitro investigations have led to the employment of menadione in different human trials in patients with gastrointestinal and lung cancer [76, 77].
Imexon is a prooxidant small molecule that depletes intracellular thiols generating oxidative stress and, subsequently, induces apoptosis [78]. Preclinical studies have demonstrated that imexon treatment increases nuclear Nrf2 levels and AP-1-DNA binding activity in myeloma cells and breast cancer cells [79]. These findings suggest that imexon leads to an adaptive response to oxidative stress involving upregulation of several antioxidant genes such as Nrf2 [79] and CuZnSOD [224]. The increased antioxidant gene expression and the enhancement of GSH levels in myeloma cell lines have been associated with the phenomenon of resistance to imexon [225].
Successful phase I trials have been completed in combination with cytotoxic chemotherapy in advanced breast, non-small cell lung cancer (NSCLC), prostate [80], and pancreatic [81] tumors. In addition, a phase II study has been carried out in patients with relapsed/refractory B-cell non-Hodgkin lymphoma [82].
Disulfiram is an acetaldehyde dehydrogenase inhibitor that induces apoptosis via GSH oxidation and proteasome inhibition [68, 83]. Preclinical studies have demonstrated that disulfiram-induced apoptosis of human melanoma cells [226] and of lymphoid malignant cells is mediated by JNK activation and Nrf2 and NF-κB inhibition [84]. A phase I/II trial with disulfiram has recently been completed in patients with metastatic melanoma and other early-phase studies are ongoing in NSCLC and treatment-refractory liver tumors [68].
Bortezomib is a proteasome inhibitor that blocks inducible I-κB degradation and consequently activates NF-κB [86, 87]. It induces cell cycle arrest and apoptosis by preventing the degradation of p21/waf1, p53, and Bax [227]. Bortezomib has been extensively studied either alone or in combination with other agents for the treatment of multiple myeloma [86] and of chronic lymphocytic leukemia (CLL) [88]. In addition, bortezomib has been demonstrated to exert cytotoxicity by increasing ROS production [228] and, in this context, our recent studies have shown that bortezomib treatment of human neuroblastoma cells is less effective as a consequence of Nrf2-mediated HO-1 upregulation [85]. Moreover, it has been reported that bortezomib induces HO-1 activity in multiple myeloma via the endoplasmic reticulum stress pathway and that HO-1 nuclear translocation confers resistance to chemotherapy and induces genetic instability in cancer cells [65].
NOV-002 is a product containing oxidized glutathione that alters the GSH/GSSG ratio and induces S-glutathionylation [91]. NOV-002-induced S-glutathionylation has been shown to have inhibitory effects on proliferation, survival and invasion of myeloid cell lines and significantly increases the efficacy of cyclophosphamide chemotherapy in a murine model of colon cancer [229]. NOV-002 has been most extensively studied with a phase III trial (NCT00347412) completed in the treatment of advanced NSCLC [92] and data is available from phase II trials in breast and ovarian cancers [230]. In a randomized phase II trial, NOV-002 in combination with standard chemotherapy has shown promising effects in patients with stage IIIb/IV of NSCLC [231]. Positive results were also obtained from a phase II trial in patients with neo adjuvant breast cancer therapy [93].
Ezatiostat hydrochloride (TLK199) is a GSH analogue that inhibits GST P1-1 leading to JNK/ERK activation and inducing apoptosis of malignant cells [94]. Treatment of leukemia cell lines with ezatiostat has been demonstrated to induce myeloblast differentiation without affecting myelopoiesis [94]. Ezatiostat has been evaluated in multiple phase I and phase II clinical trials in myelodysplastic syndrome (MDS) characterized by ineffective hematopoiesis presenting with anemia and, in some cases, neutropenia and thrombocytopenia [94].
PX-12 (1-methylpropyl 2-imidazolyl disulfide) irreversibly inactivates Trx-1 which is overexpressed in many human cancers and it is associated with aggressive tumor growth and decreased patient survival [95]. Furthermore, the antitumor activity of PX-12 is also due to a reduction of VEGF in cancer patient plasma [95] and it can be synergistically enhanced after combination of PX-12 with 5-FU in HCC cells [96]. PX-12 has shown promising pharmacokinetics and pharmacodynamics in phase Ib trials in patients with advanced solid tumors refractory to chemotherapy [97].
Dimesna (BNP7787, disodium 2,2-dithio-bis-ethane sulfonate) is a novel chemoprotective disulfide compound that targets Trx and Grx which are overexpressed in many tumors [98, 99]. Dimesna has been employed in the treatment of various solid tumors, including ovarian carcinoma and NSCLC. In addition, it is currently undergoing phase III clinical trials (NCT00966914), in combination with first-line taxane and platinum chemotherapy, in patients with diagnosed or relapsed advanced (stage IIIB/IV) NSCLC adenocarcinoma.
Motexafin gadolinium (MGd) is a Trx inhibitor that reversibly accepts electrons from NADPH, NADH, GSH, and ascorbate, with subsequent electron transfer to molecular oxygen [232]. Preclinical studies have shown that MGd alone has a proapoptotic effect in multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia [233]. MGd has been tested in a phase I trial in patients with locally advanced pancreatic or biliary cancers [97], and in a phase II trial in renal cell carcinoma [100] and in haematological malignancies [101].
Arsenic trioxide (As2O3) is an inorganic compound that has antiproliferative and apoptogenic effects on cancer cells by inducing oxidation of cysteine residues in GSH and thiol enzymes [68]. It has been approved by the European Medicines Agency and US Food and Drug Administration, for induction and consolidation of chemotherapy in adults with relapsed/refractory acute promyelocytic leukemia (APL). Moreover, As2O3, in combination with disulfiram, is being evaluated as a second-line therapy in phase I trials (NCT00571116) in patients with metastatic melanoma.
5. Conclusions
The modulation of oxidative stress is considered an important factor in the development of cancer and in the response of tumor cells to therapy [189]. As shown in this review, high ROS levels in cancer cells are a consequence of alterations in cellular metabolism and their overproduction is counteracted by elevated defense mechanisms (Figure 2).
Redox-signaling pathways that are involved in cancer growth and progression. Cancer cells escape cell death and damage induced by high ROS levels by increasing their antioxidant defenses such as GSH that contribute to lower the amount of ROS. ROS are produced by NOX in the plasma membrane and by mitochondria, and at low levels they act as second messengers by activating many protein kinases (PI3/Akt, p38 MAPK, and ATM) and transcription factors (Nrf2, NF-κB, p53, and HIF-1) able to contribute to cancer cell survival by stimulating cell proliferation, inflammation, and angiogenesis. GR, glutathione reductase.
Among antioxidants, GSH is essential for maintaining a correct redox balance, has a crucial role in the protection of cancer cells from oxidative stress, and ensures cell survival in both hypoxia and nutrient deprivation that are present in solid malignant tumors [48]. For this reason, combinations of GSH antagonists or other antioxidant inhibitors with radio or chemotherapy may be useful for killing cancer cells. This “epigenetic-genetic” therapeutic approach is in sharp contrast to the conventional strategy of targeting oncogenes and oncosuppressors, an approach that has turned out to be uneffective also for the frequent gene mutations.
As reported in this review, many of these genes are redox-sensitive transcription factors that are involved in proliferation, angiogenesis, and metastasis and are able to induce a common set of cell stress adaptive responses, thus providing a survival advantage.
Therefore, the redox-signaling pathways underlying these adaptations may represent the most critical weak point in many cancers and the signaling molecules that mediate these changes could be the next important targets for future anticancer drug discovery research.
Recently, as summarized in Table 2, many clinical trials with modulators of kinases or transcription factors associated with conventional therapy are ongoing. Although the results of some of these combined strategies seem to be promising, further studies are needed in order to identify specific markers for a more personalized therapy and to minimize the side toxic effects.
Modulators of redox signaling pathways employed in combination with anticancer agents and their effects.
The authors declare that they have no competing interests.
Acknowledgments
This work was supported by grants from MIUR-PRIN20125S38FA (M. Nitti) and Genoa University.
WisemanH.HalliwellB.Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer19963131172910.1042/bj31300172-s2.0-0030049032FinkelT.Signal transduction by mitochondrial oxidants201228774434444010.1074/jbc.r111.2719992-s2.0-84856821006Janssen-HeiningerY. M. W.MossmanB. T.HeintzN. H.FormanH. J.KalyanaramanB.FinkelT.StamlerJ. S.RheeS. G.van der VlietA.Redox-based regulation of signal transduction: principles, pitfalls, and promises200845111710.1016/j.freeradbiomed.2008.03.0112-s2.0-45049085873FormanH. J.TorresM.FukutoJ.Redox signaling2002234-235496210.1023/A:10159132296502-s2.0-4243704851LiuL.-Z.HuX.-W.XiaC.HeJ.ZhouQ.ShiX.FangJ.JiangB.-H.Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells200641101521153310.1016/j.freeradbiomed.2006.08.0032-s2.0-33749537296ZhouS.KachhapS.SunW.WuG.ChuangA.PoetaL.GrumbineL.MithaniS. K.ChatterjeeA.KochW.WestraW. H.MaitraA.GlazerC.CarducciM.SidranskyD.McFateT.VermaA.CalifanoJ. A.Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck2007104187540754510.1073/pnas.06108181042-s2.0-34250624498BenharM.EngelbergD.LevitzkiA.ROS, stress-activated kinases and stress signaling in cancer20023542042510.1093/embo-reports/kvf0942-s2.0-0035984912PantanoC.ReynaertN. L.van der VlietA.Janssen-HeiningerY. M. W.Redox-sensitive kinases of the nuclear factor-κB signaling pathway200689-101791180610.1089/ars.2006.8.17912-s2.0-33750906394RankinE. B.GiacciaA. J.The role of hypoxia-inducible factors in tumorigenesis200815467868510.1038/cdd.2008.212-s2.0-40949142209McCordJ. M.FridovichI.Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein)196924422604960552-s2.0-0014691242LiY.HuangT.-T.CarlsonE. J.MelovS.UrsellP. C.OlsonJ. L.NobleL. J.YoshimuraM. P.BergerC.ChanP. H.WallaceD. C.EpsteinC. J.Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase199511437638110.1038/ng1295-3762-s2.0-0028827252PhamC. G.BubiciC.ZazzeroniF.PapaS.JonesJ.AlvarezK.JayawardenaS.De SmaeleE.CongR.BeaumontC.TortiF. M.TortiS. V.FranzosoG.Ferritin heavy chain upregulation by NF-κB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species2004119452954210.1016/j.cell.2004.10.0172-s2.0-8344260568KangD.LeeK.-M.SueK. P.BerndtS. I.PetersU.RedingD.ChatterjeeN.WelchR.ChanockS.HuangW.-Y.HayesR. B.Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study20071681581158610.1158/1055-9965.epi-07-01602-s2.0-34548071640LiuG.ZhouW.WangL. I.ParkS.MillerD. P.XuL. L.WainJ. C.LynchT. J.SuL.ChristianiD. C.MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma20042141697910.1016/j.canlet.2004.06.0272-s2.0-4344612582OlsonS. H.CarlsonM. D. A.OstrerH.HarlapS.StoneA.WintersM.AmbrosoneC. B.Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer200493361562010.1016/j.ygyno.2004.03.0272-s2.0-2942668384WangS. S.DavisS.CerhanJ. R.HartgeP.SeversonR. K.CozenW.LanQ.WelchR.ChanockS. J.RothmanN.Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma20062791828183410.1093/carcin/bgl0132-s2.0-33747014907RayG.BatraS.ShuklaN. K.DeoS.RainaV.AshokS.HusainS. A.Lipid peroxidation, free radical production and antioxidant status in breast cancer200059216317010.1023/A:10063573304862-s2.0-0034058343TasF.HanselH.BelceA.IlvanS.ArgonA.CamlicaH.TopuzE.Oxidative stress in breast cancer2005221111510.1385/MO:22:1:0112-s2.0-18444384252YangJ.LamE. W. N.HammadH. M.OberleyT. D.OberleyL. W.Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium2002312717710.1034/j.1600-0714.2002.310202.x2-s2.0-0035999751CullenJ. J.MitrosF. A.OberleyL. W.Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer2003261232710.1097/00006676-200301000-000052-s2.0-0037215312KumaraguruparanR.KabalimoorthyJ.NaginiS.Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast200538215415810.1016/j.clinbiochem.2004.10.0122-s2.0-11844254797BenoI.StaruchovaM.VokovovaK.BatovskyM.Increased antioxidant enzyme activities in the colorectal adenoma and carcinoma19954252652692-s2.0-0028812631KahlosK.AnttilaS.AsikainenT.KinnulaK.RaivioK. O.MattsonK.LinnainmaaK.KinnulaV. L.Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma199818457058010.1165/ajrcmb.18.4.29432-s2.0-0032036317PerkinsA.NelsonK. J.ParsonageD.PooleL. B.KarplusP. A.Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling201540843544510.1016/j.tibs.2015.05.0012-s2.0-84937519769ParkM. H.JoM.KimY. R.Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases201616312310.1016/j.pharmthera.2016.03.018EglerR. A.FernandesE.RothermundK.SereikaS.De Souza-PintoN.JarugaP.DizdarogluM.ProchownikE. V.Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1200524548038805010.1038/sj.onc.12088212-s2.0-28544441664CaoJ.SchulteJ.KnightA.LeslieN. R.ZagozdzonA.BronsonR.ManevichY.BeesonC.NeumannC. A.Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity200928101505151710.1038/emboj.2009.1012-s2.0-67349147914KinnulaV. L.LehtonenS.SormunenR.Kaarteenaho-WiikR.KangS. W.RheeS. G.SoiniY.Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma2002196331632310.1002/path.10422-s2.0-0036190624LehtonenS. T.SvenskA.-M.SoiniY.PääkköP.HirvikoskiP.KangS. W.SäilyM.KinnulaV. L.Peroxiredoxins, a novel protein family in lung cancer2004111451452110.1002/ijc.202942-s2.0-3843146451YanagawaT.IwasaS.IshiiT.TabuchiK.YusaH.OnizawaK.OmuraK.HaradaH.SuzukiH.YoshidaH.Peroxiredoxin I expression in oral cancer: a potential new tumor marker20001561273510.1016/s0304-3835(00)00434-12-s2.0-18744426119ShenJ.PersonM. D.ZhuJ.AbbruzzeseJ. L.LiD.Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry200464249018902610.1158/0008-5472.CAN-04-32622-s2.0-10844252383LuW.FuZ.WangH.FengJ.WeiJ.GuoJ.Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress20143871-226127010.1007/s11010-013-1891-42-s2.0-84893845890ShiotaM.YokomizoA.KashiwagiE.TakeuchiA.FujimotoN.UchiumiT.NaitoS.Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells2011511788710.1016/j.freeradbiomed.2011.04.0012-s2.0-79957938567WangY.-G.LiL.LiuC.-H.HongS.ZhangM.-J.Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells201416656156610.1007/s12094-013-1117-y2-s2.0-84901424759WhitakerH. C.PatelD.HowatW. J.WarrenA. Y.KayJ. D.SanganT.MarioniJ. C.MitchellJ.AldridgeS.LuxtonH. J.MassieC.LynchA. G.NealD. E.Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress2013109498399310.1038/bjc.2013.3962-s2.0-84883144775WeiQ.JiangH.XiaoZ.BakerA.YoungM. R.VeenstraT. D.ColburnN. H.Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling2011108177004700910.1073/pnas.10130121082-s2.0-79955565940KimT. H.SongJ.Alcantara LlagunoS. R.MurnanE.LiyanarachchiS.PalanichamyK.YiJ.-Y.ViapianoM. S.NakanoI.YoonS. O.WuH.ParadaL. F.KwonC.-H.Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth201278e4281810.1371/journal.pone.00428182-s2.0-84865054581ElaminA.ZhuH.HassanA. M.Peroxiredoxin V: a candidate breast tumor marker of population specificity201313541549YunH.-M.ParkK.-R.ParkM. H.KimD. H.JoM. R.KimJ. Y.KimE.-C.YoonD. Y.HanS. B.HongJ. T.PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model20158013614410.1016/j.freeradbiomed.2014.12.0222-s2.0-84922251110TanakaT.HosoiF.Yamaguchi-IwaiY.NakamuraH.MasutaniH.UedaS.NishiyamaA.TakedaS.WadaH.SpyrouG.YodoiJ.Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis20022171695170310.1093/emboj/21.7.16952-s2.0-18444365267TurunenN.KarihtalaP.MäntyniemiA.SormunenR.HolmgrenA.KinnulaV. L.SoiniY.Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma2004112212313210.1111/j.1600-0463.2004.apm1120207.x2-s2.0-1642523633FujiiS.NanbuY.NonogakiH.KonishiI.MoriT.MasutaniH.YodoiJ.Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium19916871583159110.1002/1097-0142(19911001)68:760;1583::aid-cncr282068072062;3.0.co;2-n2-s2.0-0026318680NakamuraH.MasutaniH.TagayaY.YamauchiA.InamotoT.NanbuY.FujiiS.OzawaK.YodoiJ.Expression and growth-promoting effect of adult T-cell leukemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma19926982091209710.1002/1097-0142(19920415)69:8<2091::aid-cncr2820690814>3.0.co;2-x2-s2.0-0026563593SoiniY.KahlosK.NäpänkangasU.Kaarteenaho-WiikR.SäilyM.KoistinenP.PääkköP.HolmgrenA.KinnulaV. L.Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma200176175017572-s2.0-0034901958LincolnD. T.Ali EmadiE. M.TonissenK. F.ClarkeF. M.The thioredoxin-thioredoxin reductase system: over-expression in human cancer2003233B242524332-s2.0-0042807630SiesH.Glutathione and its role in cellular functions1999279-1091692110.1016/S0891-5849(99)00177-X2-s2.0-0033230043GriffithO. W.Biologic and pharmacologic regulation of mammalian glutathione synthesis1999279-1092293510.1016/S0891-5849(99)00176-82-s2.0-0033231162TraversoN.RicciarelliR.NittiM.MarengoB.FurfaroA. L.PronzatoM. A.MarinariU. M.DomenicottiC.Role of glutathione in cancer progression and chemoresistance201320131097291310.1155/2013/9729132-s2.0-84878711134HarrisI. S.TreloarA. E.InoueS.SasakiM.GorriniC.LeeK.YungK.BrennerD.Knobbe-ThomsenC. B.CoxM. A.EliaA.BergerT.CesconD. W.AdeoyeA.BrüstleA.MolyneuxS. D.MasonJ. M.LiW. Y.YamamotoK.WakehamA.BermanH. K.KhokhaR.DoneS. J.KavanaghT. J.LamC.-W.MakT. W.Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression201527221122210.1016/j.ccell.2014.11.0192-s2.0-84922783167Ravn-HarenG.OlsenA.TjønnelandA.DragstedL. O.NexøB. A.WallinH.OvervadK.Raaschou-NielsenO.VogelU.Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study200627482082510.1093/carcin/bgi2672-s2.0-33645304306Arsova-SarafinovskaZ.MatevskaN.EkenA.PetrovskiD.BanevS.DzikovaS.GeorgievV.SikoleA.ErdemO.SayalA.AydinA.DimovskiA. J.Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk2009411637010.1007/s11255-008-9407-y2-s2.0-62349122752Raaschou-NielsenO.SørensenM.HansenR. D.FrederiksenK.TjønnelandA.OvervadK.VogelU.GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer2007247229330010.1016/j.canlet.2006.05.0062-s2.0-33846931879IchimuraY.HabuchiT.TsuchiyaN.WangL.OyamaC.SatoK.NishiyamaH.OgawaO.KatoT.Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant2004172272873210.1097/01.ju.0000130942.40597.9d2-s2.0-3142583074MainesM. D.Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications1988210255725682-s2.0-0023731036KeyseS. M.TyrrellR. M.Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite19898619910310.1073/pnas.86.1.992-s2.0-0024497521RyterS. W.ChoiA. M. K.Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models200571-2809110.1089/ars.2005.7.802-s2.0-13244256816PrawanA.KunduJ. K.SurhY.-J.Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection2005711-121688170310.1089/ars.2005.7.16882-s2.0-28844446987FurfaroA. L.TraversoN.DomenicottiC.PirasS.MorettaL.MarinariU. M.PronzatoM. A.NittiM.The Nrf2/HO-1 axis in cancer cell growth and chemoresistance2016201614195817410.1155/2016/19581742-s2.0-84949883207JozkowiczA.WasH.DulakJ.Heme oxygenase-1 in tumors: is it a false friend?20079122099211710.1089/ars.2007.16592-s2.0-35848942608WasH.CichonT.SmolarczykR.RudnickaD.StopaM.ChevalierC.LegerJ. J.LackowskaB.GrochotA.BojkowskaK.RatajskaA.KiedaC.SzalaS.DulakJ.JozkowiczA.Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice200616962181219810.2353/ajpath.2006.0513652-s2.0-35848932314TsaiJ.-R.WangH.-M.LiuP.-L.ChenY.-H.YangM.-C.ChouS.-H.ChengY.-J.YinW.-H.HwangJ.-J.ChongI.-W.High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients201235646147110.1007/s13402-012-0105-52-s2.0-84879216859HillM.PereiraV.ChauveauC.ZaganiR.RemyS.TessonL.MazalD.UbillosL.BrionR.AshgarK.MashreghiM. F.KotschK.MoffettJ.DoebisC.SeifertM.BoczkowskiJ.OsinagaE.AnegonI.Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase200519141957196810.1096/fj.05-3875com2-s2.0-28744447937ChaoC.-Y.LiiC.-K.HsuY.-T.LuC.-Y.LiuK.-L.LiC.-C.ChenH.-W.Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells20133481843185110.1093/carcin/bgt1312-s2.0-84881493942WegielB.NemethZ.Correa-CostaM.BulmerA. C.OtterbeinL. E.Heme oxygenase-1: a metabolic nike201420111709172210.1089/ars.2013.56672-s2.0-84896380454TibulloD.BarbagalloI.GiallongoC.VanellaL.ConticelloC.RomanoA.SacconeS.GodosJ.Di RaimondoF.Li VoltiG.Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells2016720288682888010.18632/oncotarget.7563TibulloD.BarbagalloI.GiallongoC.La CavaP.ParrinelloN.VanellaL.StagnoF.PalumboG. A.Li VoltiG.Di RaimondoF.Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells201319152765277010.2174/13816128113191500122-s2.0-84876712355GriffithO. W.Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis19822572213704137122-s2.0-0020444895WondrakG. T.Redox-directed cancer therapeutics: molecular mechanisms and opportunities200911123013306910.1089/ars.2009.25412-s2.0-70449107252MarengoB.De CiucisC.VerzolaD.PistoiaV.RaffaghelloL.PatriarcaS.BalbisE.TraversoN.CottalassoD.PronzatoM. A.MarinariU. M.DomenicottiC.Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma200844347448210.1016/j.freeradbiomed.2007.10.0312-s2.0-38149034372MarengoB.BalbisE.PatriarcaS.De CiucisC.FurfaroA.NittiM.MarinariU. M.PronzatoM. A.TraversoN.DomenicottiC.GSH loss per se does not affect neuroblastoma survival and is not genotoxic20083211211272-s2.0-38749099759MarengoB.RaffaghelloL.PistoiaV.CottalassoD.PronzatoM. A.MarinariU. M.DomenicottiC.Reactive oxygen species: biological stimuli of neuroblastoma cell response20052281-211111610.1016/j.canlet.2005.01.0462-s2.0-23944483403DomenicottiC.MarengoB.NittiM.VerzolaD.GaribottoG.CottalassoD.PoliG.MelloniE.PronzatoM. A.MarinariU. M.A novel role of protein kinase C-δ in cell signaling triggered by glutathione depletion20036681521152610.1016/S0006-2952(03)00507-02-s2.0-0642314379O'DwyerP. J.HamiltonT. C.LaCretaF. P.GalloJ. M.KilpatrickD.HalbherrT.BrennanJ.BookmanM. A.HoffmanJ.YoungR. C.ComisR. L.OzolsR. F.Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer19961412492562-s2.0-9044254931SataN.Stumpe-KlonowskiH.HanB.HaüssingerD.NiederauC.Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells199723684485010.1016/S0891-5849(97)00064-62-s2.0-0030867361HallakM.WinT.ShpilbergO.BittnerS.GranotY.LevyI.NathanI.The anti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways2009147445947010.1111/j.1365-2141.2009.07867.x2-s2.0-70350455102MargolinK. A.AkmanS. A.LeongL. A.MorganR. J.SomloG.RaschkoJ. W.AhnC.DoroshowJ. H.Phase I study of mitomycin C and menadione in advanced solid tumors199536429329810.1007/BF006890462-s2.0-0029067681TetefM.MargolinK.AhnC.AkmanS.ChowW.LeongL.MorganR. J.Jr.RaschkoJ.SomloG.DoroshowJ. H.Mitomycin C and menadione for the treatment of lung cancer: a phase II trial199513215716210.1007/BF008728652-s2.0-0028793682DvorakovaK.PayneC. M.TomeM. E.BriehlM. M.McClureT.DorrR. T.Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon200060674975810.1016/S0006-2952(00)00380-42-s2.0-0034666730BakerA. F.LandowskiT.DorrR.TateW. R.GardJ. M. C.TavennerB. E.DragovichT.CoonA.PowisG.The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response200713113388339410.1158/1078-0432.ccr-06-08732-s2.0-34250613899MoulderS.DhillonN.NgC.HongD.WhelerJ.NaingA.TseS.La PagliaA.DorrR.HershE.BoytimM.KurzrockR.A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer201028563464010.1007/s10637-009-9273-12-s2.0-77956056306CohenS. J.ZalupskiM. M.ModianoM. R.ConklingP.PattY. Z.DavisP.DorrR. T.BoytimM. L.HershE. M.A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer201066228729410.1007/s00280-009-1162-y2-s2.0-77953073888BarrP. M.MillerT. P.FriedbergJ. W.PetersonD. R.BaranA. M.HerrM.SpierC. M.CuiH.RoeD. J.PerskyD. O.CasuloC.LittletonJ.SchwartzM.PuvvadaS.LandowskiT. H.RimszaL. M.DorrR. T.FisherR. I.BernsteinS. H.BriehlM. M.Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma201412481259126510.1182/blood-2014-04-5700442-s2.0-84907362817KonaF. R.BuacD.BurgerA. M.Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies201111333834610.2174/1568009117945197982-s2.0-79951702170ZhaJ.ChenF.DongH.ShiP.YaoY.ZhangY.LiR.WangS.LiP.WangW.XuB.Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition2014121, article 16310.1186/1479-5876-12-1632-s2.0-84903632887FurfaroA. L.PirasS.PassalacquaM.DomenicottiC.ParodiA.FenoglioD.PronzatoM. A.MarinariU. M.MorettaL.TraversoN.NittiM.HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib20141842461362210.1016/j.bbadis.2013.12.0082-s2.0-84893474094HideshimaT.RichardsonP.ChauhanD.PalombellaV. J.ElliottP. J.AdamsJ.AndersonK. C.The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells2001617307130762-s2.0-0035300479MaM. H.YangH. H.ParkerK.ManyakS.FriedmanJ. M.AltamiranoC.WuZ.-Q.BoradM. J.FrantzenM.RoussosE.NeeserJ.MikailA.AdamsJ.Sjak-ShieN.VescioR. A.BerensonJ. R.The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents200393113611442-s2.0-0037342894FaderlS.RaiK.GribbenJ.ByrdJ. C.FlinnI. W.O'BrienS.ShengS.EsseltineD.-L.KeatingM. J.Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia2006107591692410.1002/cncr.220972-s2.0-33747875167StaudtL. M.Gene expression profiling of lymphoid malignancies20025330331810.1146/annurev.med.53.082901.1039412-s2.0-0036183437RichardsonP. G.BarlogieB.BerensonJ.SinghalS.JagannathS.IrwinD.RajkumarS. V.SrkalovicG.AlsinaM.AlexanianR.SiegelD.OrlowskiR. Z.KuterD.LimentaniS. A.LeeS.HideshimaT.EsseltineD.-L.KauffmanM.AdamsJ.SchenkeinD. P.AndersonK. C.A phase 2 study of Bortezomib in relapsed, refractory myeloma2003348262609261710.1056/nejmoa0302882-s2.0-0037973279TownsendD. M.PazolesC. J.TewK. D.NOV-002, a mimetic of glutathione disulfide20081771075108310.1517/13543784.17.7.10752-s2.0-48249115538FidiasP.NovelloS.Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer201028345116512310.1200/JCO.2010.30.70742-s2.0-78650491373MonteroA. J.Diaz-MonteroC. M.DeutschY. E.HurleyJ.KoniarisL. G.RumboldtT.YasirS.JordaM.Garret-MayerE.AvisarE.SlingerlandJ.SilvaO.WelshC.SchuhwerkK.SeoP.PegramM. D.GlückS.Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer2012132121522310.1007/s10549-011-1889-02-s2.0-84857916510RazaA.GaliliN.SmithS.GodwinJ.LancetJ.MelchertM.JonesM.KeckJ. G.MengL.BrownG. L.ListA.Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome2009113266533654010.1182/blood-2009-01-1760322-s2.0-69249238115BakerA. F.DragovichT.TateW. R.RamanathanR. K.RoeD.HsuC.-H.KirkpatrickD. L.PowisG.The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma20061472839010.1016/j.lab.2005.09.0012-s2.0-31944432877LiG.-Z.LiangH.-F.LiaoB.ZhangL.NiY.-A.ZhouH.-H.ZhangE.-L.ZhangB.-X.ChenX.-P.Px-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity201579152815402-s2.0-84944350759RamanathanR. K.FakihM.ManiS.DeutschM.PerezR. P.RitterM. A.EisemanJ. L.IvyS. P.TrumpD. L.BelaniC. P.PariseR. A.PotterD. M.EgorinM. J.Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers200657446547410.1007/s00280-005-0071-y2-s2.0-30644470141BovenE.VerschraagenM.HulscherT. M.ErkelensC. A. M.HausheerF. H.PinedoH. M.Van der VijghW. J. F.BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts20023881148115610.1016/S0959-8049(02)00036-92-s2.0-0036251750HausheerF. H.ShanmugarajahD.LeverettB. D.ChenX.HuangQ.KochatH.PetluruP. N.ParkerA. R.Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase201065594195110.1007/s00280-009-1101-y2-s2.0-77649179448AmatoR. J.JacJ.Hernandez-McclainJ.Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results200862737810.3816/cgc.2008.n.0112-s2.0-58149200520LinT. S.NaumovskiL.LecaneP. S.LucasM. S.MoranM. E.CheneyC.LucasD. M.PhanS.-C.MillerR. A.ByrdJ. C.Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia200950121977198210.3109/104281909032884642-s2.0-72949103066MehtaM. P.RodrigusP.TerhaardC. H. J.RaoA.SuhJ.RoaW.SouhamiL.BezjakA.LeibenhautM.KomakiR.SchultzC.TimmermanR.CurranW.SmithJ.PhanS.-C.MillerR. A.RenschlerM. F.Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases200321132529253610.1200/JCO.2003.12.1222-s2.0-0037676125RobertC.KaraszewskaB.SchachterJ.RutkowskiP.MackiewiczA.StroiakovskiD.LichinitserM.DummerR.GrangeF.MortierL.Chiarion-SileniV.DrucisK.KrajsovaI.HauschildA.LoriganP.WolterP.LongG. V.FlahertyK.NathanP.RibasA.MartinA.-M.SunP.CristW.LegosJ.RubinS. D.LittleS. M.SchadendorfD.Improved overall survival in melanoma with combined dabrafenib and trametinib20153721303910.1056/nejmoa14126902-s2.0-84920394727TroianiT.VecchioneL.MartinelliE.CapassoA.CostantinoS.CiuffredaL. P.MorgilloF.VitaglianoD.D'AiutoE.De PalmaR.TejparS.Van CutsemE.De LorenziM.CaragliaM.BerrinoL.CiardielloF.Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells2012106101648165910.1038/bjc.2012.1292-s2.0-84860783767FarleyJ.BradyW. E.VathipadiekalV.LankesH. A.ColemanR.MorganM. A.MannelR.YamadaS. D.MutchD.RodgersW. H.BirrerM.GershensonD. M.Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study201314213414010.1016/s1470-2045(12)70572-72-s2.0-84873079682HoA. L.GrewalR. K.LeboeufR.ShermanE. J.PfisterD. G.DeandreisD.PentlowK. S.ZanzonicoP. B.HaqueS.GavaneS.GhosseinR. A.Ricarte-FilhoJ. C.DomínguezJ. M.ShenR.TuttleR. M.LarsonS. M.FaginJ. A.Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer2013368762363210.1056/nejmoa12092882-s2.0-84873681262HorganK.CookeE.HallettM. B.ManselR. E.Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity198635244463446510.1016/0006-2952(86)90764-12-s2.0-0022892593CouldwellW. T.WeissM. H.DeGiorgioC. M.WeinerL. P.HintonD. R.EhresmannG. R.ContiP. S.ApuzzoM. L. J.KornblithP.De TriboletN.TadaM.LevinV. A.OldfieldE. H.Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen199332348549010.1227/00006123-199303000-000342-s2.0-0027469702TangP. A.RoldanG.BrasherP. M. A.FultonD.RoaW.MurthaA.CairncrossJ. G.ForsythP. A.A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma200678331131610.1007/s11060-005-9104-y2-s2.0-33745773066JordanV. C.Molecular mechanisms of antiestrogen action in breast cancer1994311415210.1007/BF006896752-s2.0-0028021955NazaraliS. A.NarodS. A.Tamoxifen for women at high risk of breast cancer20146293610.2147/bctt.s437632-s2.0-84898801100GillsJ. J.DennisP. A.Perifosine: update on a novel Akt inhibitor200911210211010.1007/s11912-009-0016-42-s2.0-60349088457Van UmmersenL.BingerK.VolkmanJ.MarnochaR.TutschK.KolesarJ.ArzoomanianR.AlbertiD.WildingG.A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer200410227450745610.1158/1078-0432.CCR-03-04062-s2.0-9344270514VinkS. R.SchellensJ. H. M.BeijnenJ. H.SindermannH.EngelJ.DubbelmanR.MoppiG.HillebrandM. J. X.BartelinkH.VerheijM.Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours200680220721310.1016/j.radonc.2006.07.0322-s2.0-33748134734GhobrialI. M.RoccaroA.HongF.WellerE.RubinN.LeducR.RourkeM.ChumaS.SaccoA.JiaX.AzabF.AzabA. K.RodigS.WarrenD.HarrisB.VarticovskiL.SportelliP.LeleuX.AndersonK. C.RichardsonP. G.Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia20101631033104110.1158/1078-0432.CCR-09-18372-s2.0-76049121742RichardsonP. G.WolfJ.JakubowiakA.ZonderJ.LonialS.IrwinD.DensmoreJ.KrishnanA.RajeN.BarM.MartinT.SchlossmanR.GhobrialI. M.MunshiN.LaubachJ.AllertonJ.HideshimaT.ColsonK.PoradosuE.GardnerL.SportelliP.AndersonK. C.Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial201129324243424910.1200/jco.2010.33.97882-s2.0-81155151824WeberC. K.LiptayS.WirthT.AdlerG.SchmidR. M.Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β200011951209121810.1053/gast.2000.19458MaM.-Z.ChenG.WangP.LuW.-H.ZhuC.-F.SongM.YangJ.WenS.XuR.-H.HuY.HuangP.Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism20153681889610.1016/j.canlet.2015.07.0312-s2.0-84940467392ChowW. A.JiangC.GuanM.Anti-HIV drugs for cancer therapeutics: back to the future?2009101617110.1016/S1470-2045(08)70334-62-s2.0-57749170528HooverA. C.MilhemM. M.AndersonC. M.SunW.SmithB. J.HoffmanH. T.BuattiJ. M.Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial201537572272610.1002/hed.236642-s2.0-84928204979BrunnerT. B.GeigerM.GrabenbauerG. G.Lang-WelzenbachM.MantoniT. S.CavallaroA.SauerR.HohenbergerW.McKennaW. G.Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer200826162699270610.1200/JCO.2007.15.23552-s2.0-45749106028RenganR.MickR.PrymaD.RosenM. A.LinL. L.MaityA. M.EvansT. L.StevensonJ. P.LangerC. J.KucharczukJ.FriedbergJ.PrendergastS.SharkoskiT.HahnS. M.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response20127470971510.1097/jto.0b013e3182435aa62-s2.0-84858756851AckermannS.BeckmannM. W.ThielF.BogenriederT.Topotecan in cervical cancer20071761215122310.1111/j.1525-1438.2007.01003.x2-s2.0-35948938874ArmstrongD. K.BookmanM. A.McGuireW.BristowR. E.SchilderJ. M.A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study2007105366767110.1016/j.ygyno.2007.01.0392-s2.0-34248571510MarshallJ. L.EisenbergS. G.JohnsonM. D.HanfeltJ.DorrF. A.El-AshryD.OberstM.FuxmanY.HolmlundJ.MalikS.A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer20044426827410.3816/CCC.2004.n.0262-s2.0-19944422076TolcherA. W.ReynoL.VennerP. M.ErnstS. D.MooreM.GearyR. S.ChiK.HallS.WalshW.DorrA.EisenhauerE.A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer200288253025352-s2.0-0036023413RaoS.WatkinsD.CunninghamD.DunlopD.JohnsonP.SelbyP.HancockB. W.FeganC.CulliganD.ScheyS.MorrisT. C. M.LissitchkovT.OliverJ. W.HolmlundJ. T.Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma20041591413141810.1093/annonc/mdh3592-s2.0-4644305430FabbroD.RuetzS.BodisS.PruschyM.CsermakK.ManA.CampochiaroP.WoodJ.O'ReillyT.MeyerT.PKC412—a protein kinase inhibitor with a broad therapeutic potential200015117282-s2.0-18844478996MillwardM. J.HouseC.BowtellD.WebsterL.OlverI. N.GoreM.CopemanM.LynchK.YapA.WangY.CohenP. S.ZalcbergJ.The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study200695782983410.1038/sj.bjc.66033312-s2.0-33749320879YapT. A.YanL.PatnaikA.FearenI.OlmosD.PapadopoulosK.BairdR. D.DelgadoL.TaylorA.LupinacciL.RiisnaesR.PopeL. L.HeatonS. P.ThomasG.GarrettM. D.SullivanD. M.De BonoJ. S.TolcherA. W.First-in-man clinical trial of the oral pan-AKT inhibitor MK-206 in patients with advanced solid tumors201129354688469510.1200/JCO.2011.35.52632-s2.0-83255162603SmithM. A.GorlickR.KolbE. A.LockR.CarolH.MarisJ. M.KeirS. T.MortonC. L.ReynoldsC. P.KangM. H.ArtsJ.BashirT.JanicotM.KurmashevaR. T.HoughtonP. J.Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program201259232933210.1002/pbc.233192-s2.0-84862269393HoeK. K.VermaC. S.LaneD. P.Drugging the p53 pathway: understanding the route to clinical efficacy201413321723610.1038/nrd42362-s2.0-84895779578LambertJ. M. R.GorzovP.VeprintsevD. B.SöderqvistM.SegerbäckD.BergmanJ.FershtA. R.HainautP.WimanK. G.BykovV. J. N.PRIMA-1 reactivates mutant p53 by covalent binding to the core domain200915537638810.1016/j.ccr.2009.03.0032-s2.0-65449144050RewY.SunD.Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer201457156332634110.1021/jm500627s2-s2.0-84906087915ZhangL.WangK.LeiY.LiQ.NiceE. C.HuangC.Redox signaling: potential arbitrator of autophagy and apoptosis in therapeutic response20158945246510.1016/j.freeradbiomed.2015.08.0302-s2.0-84944393503KassG. E. N.DuddyS. K.OrreniusS.Activation of hepatocyte protein kinase C by redox-cycling quinones1989260249950710.1042/bj26004992-s2.0-0024345970SunX.WuF.DattaR.KharbandaS.KufeD.Interaction between protein kinase C δ and the c-Abl tyrosine kinase in the cellular response to oxidative stress2000275117470747310.1074/jbc.275.11.74702-s2.0-0034677930GopalakrishnaR.AndersonW. B.Ca2+-and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain198986176758676210.1073/pnas.86.17.67582-s2.0-0024724936PronzatoM. A.CottalassoD.DomenicottiC.TencaC.TraversoN.NanniG.MarinariU. M.Effects of CC14 poisoning on metabolism of dolichol in RAT liver microsomes and golgi apparatus1990114-526727710.3109/107157690090889242-s2.0-0025572310PronzatoM. A.DomenicottiC.BiasiF.ChiarpottoE.CottalassoD.ViottiP.MelloniE.MarinariU. M.PoliG.Inactivation of hepatocyte protein kinase C by carbon tetrachloride: involvement of drug's metabolic activation and prooxidant effect199017131353136010.1016/0006-291x(90)90835-b2-s2.0-0024991383DomenicottiC.PaolaD.VitaliA.NittiM.CottalassoD.MelloniE.PoliG.MarinariU. M.PronzatoM. A.Mechanisms of inactivation of hepatocyte protein kinase C isoforms following acute ethanol treatment1998254-552953510.1016/S0891-5849(98)00079-32-s2.0-0032171412DomenicottiC.PaolaD.VitaliA.NittiM.CottalassoD.PronzatoM. A.PoliG.MelloniE.MarinariU. M.Ethanol-induced effects on expression level, activity, and distribution of protein kinase C isoforms in rat liver Golgi apparatus19981141-2334310.1016/S0009-2797(98)00039-82-s2.0-0032479405AntalC. E.HudsonA. M.KangE.ZancaC.WirthC.StephensonN. L.TrotterE. W.GallegosL. L.MillerC. J.FurnariF. B.HunterT.BrognardJ.NewtonA. C.Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor2015160348950210.1016/j.cell.2015.01.0012-s2.0-84922211216LangzamL.KorenR.GalR.KugelV.PazA.FarkasA.SampsonS. R.Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder relation to degree of malignancy2001116337738510.1309/1VKK-HWH7-YVJN-7UF72-s2.0-0034848941NeillG. W.GhaliL. R.GreenJ. L.IkramM. S.PhilpottM. P.QuinnA. G.Loss of protein kinase Cα expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma20036315469246972-s2.0-0043136680OsterH.LeitgesM.Protein kinase C α but not PKCζ suppresses intestinal tumor formation in ApcMin/+ mice200666146955696310.1158/0008-5472.CAN-06-02682-s2.0-33746909044Gökmen-PolarY.MurrayN. R.VelascoM. A.GatalicaZ.FieldsA. P.Elevated protein kinase CβII is an early promotive event in colon carcinogenesis2001614137513812-s2.0-0035866371YuW.MurrayN. R.WeemsC.ChenL.GuoH.EthridgeR.CeciJ. D.EversB. M.ThompsonE. A.FieldsA. P.Role of cyclooxygenase 2 in protein kinase C βII-mediated colon carcinogenesis200327813111671117410.1074/jbc.M2114242002-s2.0-0038515329MigliaccioE.GiogioM.MeleS.PelicciG.ReboldiP.PandolfiP. P.LanfranconeL.PelicciP. G.The p66shc adaptor protein controls oxidative stress response and life span in mammals1999402675930931310.1038/463112-s2.0-0033581704WangJ.ShaoM.LiuM.PengP.LiL.WuW.WangL.DuanF.ZhangM.SongS.JiaD.RuanY.GuJ.PKCα promotes generation of reactive oxygen species via DUOX2 in hepatocellular carcinoma2015463483984510.1016/j.bbrc.2015.06.0212-s2.0-84936986307NittiM.FurfaroA. L.CevascoC.TraversoN.MarinariU. M.PronzatoM. A.DomenicottiC.PKC delta and NADPH oxidase in retinoic acid-induced neuroblastoma cell differentiation201022582883510.1016/j.cellsig.2010.01.0072-s2.0-77951887536JacksonD. N.FosterD. A.The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival200418662763610.1096/fj.03-0979rev2-s2.0-1842454982RioboN. A.HainesG. M.EmersonC. P.Jr.Protein kinase C-δ and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling200666283984510.1158/0008-5472.can-05-25392-s2.0-31544461492GrinerE. M.KazanietzM. G.Protein kinase C and other diacylglycerol effectors in cancer20077428129410.1038/nrc21102-s2.0-33947603008NabhaS. M.GlarosS.HongM.LykkesfeldtA. E.SchiffR.OsborneK.ReddyK. B.Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells200524193166317610.1038/sj.onc.12085022-s2.0-18844427567MarengoB.de CiucisC.RicciarelliR.PassalacquaM.NittiM.ZinggJ.-M.MarinariU. M.PronzatoM. A.DomenicottiC.PKCδ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage201162, article e1466110.1371/journal.pone.00146612-s2.0-79951534617Ruhul AminA. R. M.SengaT.OoM. L.ThantA. A.HamaguchiM.Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1β: a role for the dual signalling pathways, Akt and Erk20038651552310.1046/j.1365-2443.2003.00652.x2-s2.0-0038339538ChangL.GrahamP. H.HaoJ.NiJ.BucciJ.CozziP. J.KearsleyJ. H.LiY.Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance2013410, article e87510.1038/cddis.2013.4072-s2.0-84887495550KangS. S.KwonT.KwonD. Y.DoS. I.Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit199927419130851309010.1074/jbc.274.19.130852-s2.0-0033532056LeonarduzziG.SotteroB.TestaG.BiasiF.PoliG.New insights into redox-modulated cell signaling201117363994400610.2174/1381612117987649062-s2.0-84855243972LosM.MaddikaS.ErbB.Schulze-OsthoffK.Switching Akt: from survival signaling to deadly response200931549249510.1002/bies.2009000052-s2.0-66449118214XuJ.TianW.MaX.GuoJ.ShiQ.JinY.XiJ.XuZ.The molecular mechanism underlying morphine-induced akt activation: roles of protein phosphatases and reactive oxygen species201161230331110.1007/s12013-011-9213-52-s2.0-80955151555LeslieN. R.The redox regulation of PI 3-kinase-dependent signaling200689-101765177410.1089/ars.2006.8.17652-s2.0-33750906556IchijoH.NishidaE.IrieK.Ten DijkeP.SaitohM.MoriguchiT.TakagiM.MatsumotoK.MiyazonoK.GotohY.Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways19972755296909410.1126/science.275.5296.902-s2.0-14444281569GoldmanE. H.ChenL.FuH.Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation200427911104421044910.1074/jbc.m3111292002-s2.0-1642410790SaitohM.NishitohH.FujiiM.TakedaK.TobiumeK.SawadaY.KawabataM.MiyazonoK.IchijoH.Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 119981792596260610.1093/emboj/17.9.25962-s2.0-0032080283ThorntonT. M.RinconM.Non-classical p38 map kinase functions: cell cycle checkpoints and survival20095144522-s2.0-60149093582HuiL.BakiriL.MairhorferA.SchweiferN.HaslingerC.KennerL.KomnenovicV.ScheuchH.BeugH.WagnerE. F.p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway200739674174910.1038/ng20332-s2.0-34249334506VenturaJ. J.TenbaumS.PerdigueroE.HuthM.GuerraC.BarbacidM.PasparakisM.NebredaA. R.p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation200739675075810.1038/ng20372-s2.0-34249807348KimM.-S.LeeE.-J.KimH.-R. C.MoonA.p38 kinase is a key signaling molecule for H-ras-induced cell motility and invasive phenotype in human breast epithelial cells20036317545454612-s2.0-0141482096PlataniasL. C.Map kinase signaling pathways and hematologic malignancies2003101124667467910.1182/blood-2002-12-36472-s2.0-0038792224HalawaniD.MondehR.StantonL.-A.BeierF.p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation200423203726373110.1038/sj.onc.12074222-s2.0-2442644183MarengoB.De CiucisC. G.RicciarelliR.FurfaroA. L.CollaR.CanepaE.TraversoN.MarinariU. M.PronzatoM. A.DomenicottiC.P38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment20134, article e58910.1038/cddis.2013.1182-s2.0-84876887873ShiX.ZhangY.ZhengJ.PanJ.Reactive oxygen species in cancer stem cells201216111215122810.1089/ars.2012.45292-s2.0-84859829553CosentinoC.GriecoD.CostanzoV.ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair201130354655510.1038/emboj.2010.3302-s2.0-79551580561YinH.GlassJ.The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling201169e24080MolchadskyA.RivlinN.BroshR.RotterV.SarigR.P53 is balancing development, differentiation and de-differentiation to assure cancer prevention20103191501150810.1093/carcin/bgq1012-s2.0-77956280751HauptY.MayaR.KazazA.OrenM.Mdm2 promotes the rapid degradation of p531997387663029629910.1038/387296a02-s2.0-0030905284BodeA. M.DongZ.Post-translational modification of p53 in tumorigenesis200441079380510.1038/nrc14552-s2.0-4944255743KruseJ.-P.GuW.Modes of p53 regulation2009137460962210.1016/j.cell.2009.04.0502-s2.0-65549120715PolyakK.XiaY.ZweierJ. L.KinzlerK. W.VogelsteinB.A model for p53-induced apoptosis1997389664830030510.1038/385252-s2.0-0030930366RiveraA.MaxwellS. A.The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway200528032293462935410.1074/jbc.M5048522002-s2.0-23844477888SablinaA. A.BudanovA. V.IlyinskayaG. V.AgapovaL. S.KravchenkoJ. E.ChumakovP. M.The antioxidant function of the p53 tumor suppressor200511121306131310.1038/nm13202-s2.0-28644447272ItalianoD.LenaA. M.MelinoG.CandiE.Identification of NCF2/p67phox as a novel p53 target gene201211244589459610.4161/cc.228532-s2.0-84871529502VousdenK. H.RyanK. M.P53 and metabolism200991069170010.1038/nrc27152-s2.0-70349459599HussainS. P.AmstadP.HeP.RoblesA.LupoldS.KanekoI.IchimiyaM.SenguptaS.MechanicL.OkamuraS.HofsethL. J.MoakeM.NagashimaM.ForresterK. S.HarrisC. C.p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis20046472350235610.1158/0008-5472.can-2287-22-s2.0-11144356558NamS. Y.SabapathyK.P53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1201130444476448610.1038/onc.2011.1502-s2.0-80455164743BensaadK.TsurutaA.SelakM. A.VidalM. N. C.NakanoK.BartronsR.GottliebE.VousdenK. H.TIGAR, a p53-inducible regulator of glycolysis and apoptosis2006126110712010.1016/j.cell.2006.05.0362-s2.0-33745918951GorriniC.HarrisI. S.MakT. W.Modulation of oxidative stress as an anticancer strategy2013121293194710.1038/nrd40022-s2.0-84889575198HuW.ZhangC.WuR.SunY.LevineA.FengZ.Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function2010107167455746010.1073/pnas.10010061072-s2.0-77952212178HuR.SawC. L.YuR.KongA.-N.Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory201013111679169810.1089/ars.2010.32762-s2.0-77958114117WakabayashiN.SlocumS. L.SkokoJ. J.ShinS.KenslerT. W.When NRF2 talks, who's listening?201013111649166310.1089/ars.2010.32162-s2.0-77956915802HarveyC. J.ThimmulappaR. K.SinghA.BlakeD. J.LingG.WakabayashiN.FujiiJ.MyersA.BiswalS.Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress200946444345310.1016/j.freeradbiomed.2008.10.0402-s2.0-58649100237NordbergJ.ArnérE. S. J.Reactive oxygen species, antioxidants, and the mammalian thioredoxin system200131111287131210.1016/S0891-5849(01)00724-92-s2.0-0035584857PadmanabhanB.TongK. I.OhtaT.NakamuraY.ScharlockM.OhtsujiM.KangM.-I.KobayashiA.YokoyamaS.YamamotoM.Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer200621568970010.1016/j.molcel.2006.01.0132-s2.0-33344456501SinghA.MisraV.ThimmulappaR. K.LeeH.AmesS.HoqueM. O.HermanJ. G.BaylinS. B.SidranskyD.GabrielsonE.BrockM. V.BiswalS.Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer2006310, article e42010.1371/journal.pmed.00304202-s2.0-33750885385OhtaT.IijimaK.MiyamotoM.NakaharaI.TanakaH.OhtsujiM.SuzukiT.KobayashiA.YokotaJ.SakiyamaT.ShibataT.YamamotoM.HirohashiS.Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth20086851303130910.1158/0008-5472.CAN-07-50032-s2.0-40449107193NioiP.NguyenT.A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity2007362481682110.1016/j.bbrc.2007.08.0512-s2.0-34548577395ShibataT.OhtaT.TongK. I.KokubuA.OdogawaR.TsutaK.AsamuraH.YamamotoM.HirohashiS.Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy200810536135681357310.1073/pnas.08062681052-s2.0-51649130168DevarakondaS.MorgenszternD.GovindanR.Genomic alterations in lung adenocarcinoma2015167e342e35110.1016/S1470-2045(15)00077-72-s2.0-84937413847ArnérE. S. J.HolmgrenA.Physiological functions of thioredoxin and thioredoxin reductase2000267206102610910.1046/j.1432-1327.2000.01701.x2-s2.0-0033775891YouA.NamC.-W.WakabayashiN.YamamotoM.KenslerT. W.KwakM.-K.Transcription factor Nrf2 maintains the basal expression of Mdm2: an implication of the regulation of p53 signaling by Nrf22011507235636410.1016/j.abb.2010.12.0342-s2.0-79951956638JaramilloM. C.ZhangD. D.The emerging role of the Nrf2-Keap1 signaling pathway in cancer201327202179219110.1101/gad.225680.1132-s2.0-84885944468FurfaroA. L.MacAyJ. R. Z.MarengoB.NittiM.ParodiA.FenoglioD.MarinariU. M.PronzatoM. A.DomenicottiC.TraversoN.Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1201252248849610.1016/j.freeradbiomed.2011.11.0072-s2.0-84855427508ChenZ. J.Ubiquitin signalling in the NF-κB pathway20057875876510.1038/ncb0805-7582-s2.0-23144449789MiyamotoS.Nuclear initiated NF-κB signaling: NEMO and ATM take center stage201121111613010.1038/cr.2010.1792-s2.0-78650873024MorganM. J.LiuZ.-G.Crosstalk of reactive oxygen species and NF-κB signaling201121110311510.1038/cr.2010.1782-s2.0-78650894319FlohéL.ToppoS.CozzaG.UrsiniF.A comparison of thiol peroxidase mechanisms201115376378010.1089/ars.2010.33972-s2.0-79959338971AntunesF.HanD.Redox regulation of NF-κB: from basic to clinical research20091192055205610.1089/ars.2009.26592-s2.0-68949199779WangF.YangJ. L.YuK. K.Activation of the NF-kappaB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma2015141, article 10MyantK. B.CammareriP.McGheeE. J.RidgwayR. A.HuelsD. J.CorderoJ. B.SchwitallaS.KalnaG.OggE.-L.AthineosD.TimpsonP.VidalM.MurrayG. I.GretenF. R.AndersonK. I.SansomO. J.ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation201312676177310.1016/j.stem.2013.04.0062-s2.0-84878889056Grosjean-RaillardJ.TaillerM.AdèsL.PerfettiniJ.-L.FabreC.BraunT.De BottonS.FenauxP.KroemerG.ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia20092881099110910.1038/onc.2008.4572-s2.0-61349144249RosatoR. R.KollaS. S.HockS. K.AlmenaraJ. A.PatelA.AminS.AtadjaP.FisherP. B.DentP.GrantS.Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway201028513100641007710.1074/jbc.m109.0952082-s2.0-77951241720WangG. L.JiangB.-H.RueE. A.SemenzaG. L.Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension199592125510551410.1073/pnas.92.12.55102-s2.0-0029051439KallioP. J.PongratzI.GradinK.McGuireJ.PoellingerL.Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor199794115667567210.1073/pnas.94.11.56672-s2.0-0030914648KimJ.-W.GaoP.LiuY.-C.SemenzaG. L.DangC. V.Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1200727217381739310.1128/MCB.00440-072-s2.0-35649014840SemenzaG. L.Targeting HIF-1 for cancer therapy200331072173210.1038/nrc11872-s2.0-0142166332SemenzaG. L.Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics201029562563410.1038/onc.2009.4412-s2.0-76349095132SemenzaG. L.Regulation of cancer cell metabolism by hypoxia-inducible factor 12009191121610.1016/j.semcancer.2008.11.0092-s2.0-60549083256MovafaghS.CrookS.VoK.Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate2015116569670310.1002/jcb.250742-s2.0-84924311131WilsonW. R.HayM. P.Targeting hypoxia in cancer therapy201111639341010.1038/nrc30642-s2.0-79957534572OzbenT.Oxidative stress and apoptosis: impact on cancer therapy20079692181219610.1002/jps.208742-s2.0-34748858784RenschlerM. F.The emerging role of reactive oxygen species in cancer therapy200440131934194010.1016/j.ejca.2004.02.0312-s2.0-4143066896SamulitisB. K.LandowskiT. H.DorrR. T.Correlates of imexon sensitivity in human multiple myeloma cell lines20064719710910.1080/104281905002662102-s2.0-30844452908DvorakovaK.PayneC. M.TomeM. E.BriehlM. M.VasquezM. A.WaltmireC. N.CoonA.DorrR. T.Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells2002131851952-s2.0-0036052593CenD.BraytonD.ShahandehB.MeyskensF. L.Jr.FarmerP. J.Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells200447276914692010.1021/jm049568z2-s2.0-11144224746LiuF.-T.AgrawalS. G.GribbenJ. G.YeH.DuM.-Q.NewlandA. C.JiaL.Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL200811152797280510.1182/blood-2007-08-1104452-s2.0-41949136647HouJ.CuiA.SongP.HuaH.LuoT.JiangY.Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells201511171271810.3892/mmr.2014.27362-s2.0-84916196021MonteroA. J.JassemJ.Cellular redox pathways as a therapeutic target in the treatment of cancer201171111385139610.2165/11592590-000000000-000002-s2.0-79961196710MatulonisU. A.HorowitzN. S.CamposS. M.LeeH.LeeJ.KrasnerC. N.BerlinS.RocheM. R.DuskaL. R.PereiraL.KendallD.PensonR. T.Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer200826355761576610.1200/jco.2008.17.02822-s2.0-57449098425TownsendD. M.TewK. D.Pharmacology of a mimetic of glutathione disulfide, NOV-0022009632757810.1016/j.biopha.2008.08.0192-s2.0-58949103855MagdaD.LecaneP.MillerR. A.LeppC.MilesD.MesfinM.BiaglowJ. E.HoV. V.ChawannakulD.NagpalS.KaramanM. W.HaciaJ. G.Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines20056593837384510.1158/0008-5472.CAN-04-40992-s2.0-20944432604MagdaD.MillerR. A.Motexafin gadolinium: a novel redox active drug for cancer therapy200616646647610.1016/j.semcancer.2006.09.0022-s2.0-33751181914